Skip to main content

AMRX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

AMRX Price
Price Chart

Forward-looking statistics

Beta
0.87
Risk
39.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees6K
Market cap$2.1B

Fundamentals

Enterprise value$5.1B
Revenue$2.8B
Revenue per employee—
Profit margin-0.46%
Debt to equity-43.43

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.04
Dividend per share—
Revenue per share$9.13
Avg trading volume (30 day)$14M
Avg trading volume (10 day)$16M
Put-call ratio—

Macro factor sensitivity

Growth+5.3
Credit+7.5
Liquidity-2.1
Inflation+1.2
Commodities+1.3
Interest Rates-3.5

Valuation

Dividend yield0.00%
PEG Ratio11.86
Price to sales1.39
P/E Ratio11.86
Enterprise Value to Revenue1.81
Price to book-44.10

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?

Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Investment Research (June 30, 2025)
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio.

Benzinga (February 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free